BioPharmX starts phase 2 clinical study under US FDA IND for BPX-01
The company will evaluate effectiveness in decreasing the number of acne-causing bacteria in patients at four weeks and assess the drug’s safety and tolerability. It is the first
BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.
The ARRIVE Study is a randomized, double-blinded, allocation-concealed, placebo-controlled, proof-of-concept Phase IIa clinical trial, which is an investigator-initiated study, and is being conducted at the NAFLD Research Center,